http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2594125-C
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9eceda7a888381343daebf50209b1d84 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96455 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
filingDate | 2005-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2016-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13a6f5a029a18e8eacead9fa795db093 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0da554785c2e517e39628cb3279be460 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87e79b12d896c4a2aab06566f65477ce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f86d325676a6da9cb31e6e0e4b3f9697 |
publicationDate | 2016-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CA-2594125-C |
titleOfInvention | Mrna ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer |
abstract | Described herein are methods and kits for prognosis of prostate cancer in a subject. The methods comprises: (a) determining the ratio of PCA3 and PSA expression in a urine sample and (b) correlating the value of the PCA3/PSA ratio with the aggressiveness and mortality risk of prostate cancer in the subject. Kits for prognosing prostate cancer are also described. More particularly, the present invention features a method for prognosing prostate cancer in a biological sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of PSA in the biological sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of PSA; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value. |
priorityDate | 2004-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 298.